RxDoctor Payments Data

Elizabeth Ebeywa

Adult Health · Homewood, ILNPI 1205552114

Payments from drug & device makers

$652in general payments, 2019–2025

Across 21 payments — averaging $31.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Insulet Corporation$140
  • Dexcom, Inc.$115
  • Boehringer Ingelheim$65
  • Novo Nordisk$56
  • Lilly USA, LLC$48
  • Mannkind Corporation$43
  • plus $185 from 7 others

What the payments were for

  • Food & beverage$58990%
  • Education$437%
  • Other$203%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$652 in reported general payments places this provider in the 65th percentile of 553 adult health providers in Illinois.

See all adult health providers in Illinois

Medicare billing

Part B allowed, 2024
$28,957
Medicare patients
33
Services billed
257

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban78$23,647
JardianceEmpagliflozin94$22,878
Isosorbide Dinitrate35$16,091
MounjaroTirzepatide14$14,869
FarxigaDapagliflozin Propanediol40$9,661
LokelmaSodium Zirconium Cyclosilicate30$8,054
InvokanaCanagliflozin11$3,316
Midodrine Hcl76$3,126
Atorvastatin Calcium380$2,919
CholestyramineCholestyramine (With Sugar)11$1,835
Metoprolol Succinate96$1,339
FenofibrateFenofibrate Nanocrystallized65$1,292
Lactulose54$1,128
Heparin SodiumHeparin Sodium,porcine14$889
Levothyroxine Sodium104$884

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$65$22,87894 claims
AstraZenecaFarxiga, Lokelma$15$17,71570 claims
Lilly USA, LLCMounjaro$48$14,86914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 553 adult health providers in Illinois.

Other adult health in Homewood

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →